The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 16, 2016
Filed:
Oct. 16, 2013
Applicants:
Timothy Cardozo, New York, NY (US);
Michele Pagano, New York, NY (US);
Lily Wu, Freeport, NY (US);
Leslie I. Gold, New York, NY (US);
Inventors:
Timothy Cardozo, New York, NY (US);
Michele Pagano, New York, NY (US);
Lily Wu, Freeport, NY (US);
Leslie I. Gold, New York, NY (US);
Assignee:
New York University, New York, NY (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 513/04 (2006.01); G01N 33/50 (2006.01); C07D 239/36 (2006.01); C07D 417/06 (2006.01); C07D 249/12 (2006.01); C07D 471/04 (2006.01); C07D 207/44 (2006.01); C07D 277/34 (2006.01); C07C 251/80 (2006.01); C07D 307/54 (2006.01); G01N 33/574 (2006.01); A61K 31/341 (2006.01); A61K 31/4015 (2006.01); A61K 31/4196 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5011 (2013.01); A61K 31/341 (2013.01); A61K 31/4015 (2013.01); A61K 31/4196 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/4439 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); C07C 251/80 (2013.01); C07D 207/44 (2013.01); C07D 239/36 (2013.01); C07D 249/12 (2013.01); C07D 277/34 (2013.01); C07D 307/54 (2013.01); C07D 417/06 (2013.01); C07D 471/04 (2013.01); C07D 513/04 (2013.01); G01N 33/574 (2013.01); G01N 2500/02 (2013.01);
Abstract
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.